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INTRODUCTION
Breast cancer is a leading cause of cancer-related death in 
woman worldwide. Mammography and other diagnostic tools 
permit earlier detection, while adjuvant chemotherapies extend 
survival. Death from breast cancer occurs primarily through 
distant metastasis. Nearly 30% of patients with axillary node-
negative breast cancer and almost 50% of those with axillary 
node-positive breast cancer will eventually experience tumor 
recurrence following surgical resection with adjuvant chemo-
therapy due to occult micrometastatic cells in their blood [1]. 
Metastasis stems from minimal residual disease (MRD) and 
the presence of single disseminated or circulating tumor cells 
(CTC) that are undetectable even by high resolution imaging 
technologies [2,3].
Disseminated tumor cells (DTC) are known to predict un-
favorable outcomes in breast cancer patients, but the detection 
of DTC in the bone marrow is cumbersome, painful and inva-
sive [4,5]. Many clinicians are turning to CTC research because 
CTC detection is well tolerated, minimally invasive and easily 
reproduced. The value of peripheral blood CTC in prognosis 
was first evaluated in patients with metastatic breast cancer 
and more recently evaluated in the general breast cancer pop-
ulation [6-10].
Cytokeratin-20 (CK-20) presents a valid marker for CTC in 
peripheral blood because it is not expressed in normal healthy 
hematologic tissues or in benign breast disease, including in-
flammatory breast disease therefore, CK-20 is used as a mark-
er of hematogenous micrometastasis and a reverse transcrip-
tase polymerase chain reaction (RT-PCR) target for the detec-
tion of breast CTC in patients with breast cancer [11-13]. 
Breast cancer can be classified in intrinsic subtypes accord-
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Purpose: Circulating tumor cells (CTC) clearly correlate with unfa-
vorable outcomes for patients with metastatic breast cancer, but 
the long-term prognostic implications of CTC for molecular sub-
types of operable breast cancer are not yet known. We explored 
the relationships between previously established prognostic fac-
tors and CTC in operable breast cancer, and the significance of 
CTC by breast cancer molecular subtype. Methods: We retro-
spectively evaluated 166 patients with operable breast cancer 
(stage I-IIIA) diagnosed from April 1997 to May 2003. CTC were 
detected using cytokeratin- 20 (CK-20) mRNA expression in     
peripheral blood samples that were collected just prior to surgery 
under general anesthesia. Clinicopathological characteristics of 
the cancer were analyzed according to CTC status. Metastasis-
free survival (MFS) and overall survival (OS) were analyzed accord-
ing to CTC status and breast cancer molecular subtype. Results: 
CK-20 mRNA-positive CTC was detected in 37 of 166 patients 
(22.3%) and was not correlated with any previous clinical factors 
in univariate analysis (p>0.05). After a median follow-up of 100 
months, the patients with CK-20 mRNA-positive CTC had less 
favorable outcomes in terms of MFS and OS than those without 
detectable CTC (log-rank p<0.05). Among molecular subtypes 
of operable breast cancer, the patients with CK-20 mRNA-posi-
tive CTC had shorter MFS and OS in triple negative and human 
epidermal growth factor 2 (HER2) breast cancer subtype (log-rank, 
p<0.05). Conclusion: CK-20 mRNA-positive CTC may lend insight 
into tumor progression as a prognostic indicator especially in the 
triple negative and HER2 subtypes of operable breast cancer.
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ing to distinct gene profile [14,15]. This molecular classifica-
tion includes four main subtypes of breast cancer: luminal A 
subtype, luminal B subtype, human epidermal growth factor 
receptor 2 (HER2) subtype, and basal-like tumors [16]. Breast 
cancers have different clinical features according to their intrin-
sic subtypes, accordingly, they may have a different prognostic 
CTC value according to own subtype [17]. CTC can exhibit 
different characteristics compared to primary tumors [18]. 
Until now, few studies have addressed the prognostic signifi-
cance of CTC according to breast cancer molecular subtype, 
particularly with regard to long-term follow-up.
In this study, we analyzed the relationships between CK-20 
mRNA-positive CTC in the peripheral blood and previously 
recognized factors in operable breast cancer, and we evaluated 
the different prognostic significance of CK-20 mRNA-positive 
CTC according to the 4 breast cancer molecular subtypes.
METHODS
Materials
Peripheral blood samples were obtained from breast cancer 
patients who underwent surgery at Korea University Anam 
Hospital from April 1997 to May 2003. Each patient provided 
informed consent prior to the blood collection. The samples 
were collected as described to study the sensitivity of CK-20 
mRNA expression for detecting CTC and the relationship be-
tween the established prognostic parameters and CK-20 mRNA-
positive CTC in breast cancer [12,19]. Based on retrospective 
reviews of medical records, patients were selected for this study 
according to the following inclusion criteria: 1) female gender; 
2) diagnosis of invasive ductal carcinoma; 3) stage I-IIIA accord-
ing to the American Joint Committee on Cancer staging sys-
tem (6th edition) defined as an operable breast cancer; 4) data 
available to determine estrogen receptor (ER), progesterone 
receptor (PR), and HER2 status; and 5) no previous surgery 
or other treatments for the primary tumor. Accordingly, 166 
patients met the criteria and were entered into this study.
All patients included in this study received treatments judged 
appropriate for the stage and hormone receptor status of their 
tumors. Surgical procedures included breast-conserving sur-
gery and modified radical mastectomy. Breast-conserving sur-
gery included lumpectomy, quadrantectomy and wedge resec-
tion with axillary lymph node dissection. All patients who 
underwent breast-conserving surgery received radiation ther-
apy and all ER+ patients received tamoxifen therapy (20 mg 
daily for 5 years). Patients with HER2-positive tumor did not 
receive adjuvant treatment with trastuzumab (Herceptin
®; 
Genentech, San Francisco, USA).
Sample collection and RT-PCR amplification of CK-20 mRNA
The blood samples (10 mL) were collected just prior to sur-
gery under general anesthesia from the ante-cubital vein after 
several milliliters of blood were drained to avoid contamina-
tion with skin epithelial cells. The blood samples were collect-
ed in ethylenediaminetetraacetic acid-treated tubes, placed on 
ice, and transported immediately to the laboratory for RNA 
isolation. RT-PCR amplification of CK-20 mRNA was per-
formed as previously described [12,19].
Immunohistochemistry for ER, PR, HER2, and molecular 
subtypes
ER (DAKO, Glostrup, Denmark) and PR (DAKO) status 
were recorded as positive if >1% of the tumor nuclei were 
immunoreactive. Otherwise, ER and PR were recorded as 
negative. For HER2 status (Labvision, Fremont, USA), 0 and 
1+ were considered negative and 3+ was considered positive 
by immunohistochemistry (IHC). Fluorescence in situ hybrid-
ization (FISH) was not performed for 2+ HER2 status by IHC, 
and HER2 2+ patients were excluded from the study. Molecu-
lar subtypes were assigned according to ER, PR, or HER2 sta-
tus: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ 
and/or PR+, HER2+), triple negative (ER-, PR-, HER2-), and 
HER2 (ER-, PR-, HER2+).
Statistical analysis
The relationships between CK-20 mRNA-positive CTC and 
clinical factors were evaluated using Fisher’s exact test and 
Pearson’s chi-square test. Metastasis-free survival (MFS) and 
overall survival (OS) according to molecular subtypes were 
estimated using the Kaplan-Meier log-rank method. To evalu-
ate independent prognostic factor and relative risk, multivari-
ate analyses were performed using the Cox proportional haz-
ards model and logistic regression. All statistical tests were 
performed at the 5% significance level (p<0.05). All statistical 
analyses were performed using SPSS version 18.0 for Windows 
(SPSS Inc., Chicago, USA). 
RESULTS
Patients characteristics
The characteristics of the 166 patients are presented in Table 
1. The patients’ mean age was 49.5±10.4 years (range, 26-78 
years). The median follow-up time was 100.6 months (range, 
0.4-163.9 months). The CK-20 mRNA-positive CTC was de-
tected in 37 (22.3%) of 166 patients. According to breast can-
cer subtype, 73 patients were identified as luminal A (44.0%), 
40 as luminal B (24.1%), 36 as triple negative (21.7%), and 17 
as HER2 (10.2%). 36   Seong Bae Hwang, et al.
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Table 1. Characteristics in patients with operable breast cancer
Characteristics
Overall
No. (%)
CTC negative
No. (%)
CTC positive
No. (%)
p-value
Age (yr)
<35 13 (7.8) 8 (6.2) 5 (13.5) 0.303
≥35 to ≤50 78 (47.0) 63 (48.8) 15 (40.5)
50< 75 (45.2) 58 (45.0) 17 (46.0)
T stage
1 66 (39.8) 54 (41.9) 12 (32.4) 0.313
2 83 (50.0) 64 (49.6) 19 (51.4)
3 17 (10.2) 11 (8.5) 6 (16.2)
N stage
0 84 (50.6) 70 (54.3) 14 (37.8) 0.209
1 51 (30.7) 37 (28.7) 14 (37.8)
2 31 (18.7) 22 (17.0) 9 (24.4)
TNM stage
I 43 (25.9) 37 (28.7) 6 (16.2) 0.071
IIA 58 (34.9) 44 (34.1) 14 (37.8)
IIB 29 (17.5) 25 (19.4) 4 (10.8)
IIIA 36 (21.7) 23 (17.8) 13 (35.2)
Lymphatic invasion
No 136 (81.9) 108 (83.7) 28 (75.7) 0.262
Yes 30 (18.1) 21 (16.3) 9 (24.3)
Vascular invasion
No 160 (96.4) 125 (96.9) 35 (94.6) 0.508
Yes 6 (3.6) 4 (3.1) 2 (5.4)
p53
Negative 92 (55.4) 72 (55.8) 20 (54.1) 0.078
Positive 74 (44.6) 57 (44.2) 17 (45.9)
ER
Negative 63 (38.0) 48 (37.2) 15 (40.5) 0.713
Positive 103 (62.0) 81 (62.8) 22 (59.5)
Characteristics
Overall
No. (%)
CTC negative
No. (%)
CTC positive
No. (%)
p-value
PR
Negative 59 (35.5) 43 (33.3) 16 (43.2) 0.267
Positive 107 (64.5) 86 (66.7) 21 (56.8)
HER2
Negative (0-1+) 109 (65.7) 84 (65.1) 25 (67.6) 0.782
Positive (3+) 57 (34.3) 45 (34.9) 12 (32.4)
Subtypes
Luminal A 73 (44.0) 57 (44.2) 16 (43.2) 0.756
Luminal B 40 (24.1) 33 (25.6) 7 (18.9)
TNBC 36 (21.7) 27 (20.9) 9 (24.3)
HER2 17 (10.2) 12 (9.3) 5 (13.5)
Surgery
MRM 108 (65.1) 81 (62.8) 27 (73.0) 0.252
BCS 58 (34.9) 48 (37.2) 10 (27.0)
RT
No 75 (45.2) 58 (45.0) 17 (45.9) 0.916
Yes 91 (54.8) 71 (55.0) 20 (54.1)
Chemotherapy
No 22 (13.3) 18 (14.0) 4 (10.8) 0.619
Yes 144 (86.7) 111 (86.0) 33 (89.2)
Recurrence
No 130 (78.3) 107 (82.9) 23 (62.2) 0.023
Locoregional  9 (5.4) 6 (4.7) 3 (8.1)
Systemic 27 (16.3) 16 (12.4) 11 (29.7)
Breast cancer-specific death
No 146 (88.0) 117 (90.7) 29 (78.4) 0.042
Yes 20 (12.0) 12 (9.3) 8 (21.6)
CTC=circulating tumor cells; ER=estrogen receptor; PR=progesterone receptor; TNBC=triple negative breast cancer; HER2=human epidermal growth factor   
receptor 2; MRM=modified radical mastectomy; BCS=breast-conserving surgery; RT=radiation therapy. 
Figure 1. Prognostic significance of circulating tumor cells (CTC) in operable breast cancer. (A) Metastasis-free survival in operable breast cancer. (B) 
Overall survival in operable breast cancer. *log-rank test.
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No significant differences were observed in the distribution 
of CTC-positive status according to molecular subtype of breast 
cancer. CTC-positive status was not significantly associated 
with any previously established prognostic factor and was cor-
related only with recurrence and breast cancer-specific death in 
operable breast cancer (p=0.023 and p=0.042, respectively) 
(Table 1).
Prognostic impact of CK-20 mRNA-positive CTC before surgery
Overall, locoregional recurrences were observed in 9 patients 
(5.4%), while systemic recurrences were seen in 27 patients 
(16.3%). During follow-up, 20 breast cancer-specific deaths 
occurred (12.0%). Patients with positive CTC status had sig-
nificantly shorter MFS and OS in operable breast cancer (log-
rank, p=0.013 and p=0.042, respectively) (Figure 1). Positive 
CTC was not associated with MFS or OS in patients with either 
early breast cancer (tumor, node, metastasis [TNM] stage I, II) 
or advanced breast cancer (TNM stage IIIA) (log-rank, p>0.05) 
(Figure 2). Positive CTC was not significantly related with 
MFS or OS in the lymph node-negative patient group, and 
also was not related with OS in lymph node positive patient 
group (log-rank, p>0.05) (Figure 3). Positive CTC was asso-
ciated with shorter MFS in the lymph node-positive patient 
group only (log-rank, p=0.037) (Figure 3B).
Figure 2. Different prognostic significances of circulating tumor cells (CTC) according to the American Joint Committee on Cancer tumor stage (early 
vs. advanced). (A) Metastasis-free survival (MFS) in early breast cancer patients. (B) MFS in patients with advanced breast cancer. (C) Overall survival 
(OS) in patients with early breast cancer. (D) OS in patients with advanced breast cancer. *log-rank test.
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Luminal A and luminal B subtypes did not differ signifi-
cantly in MFS (log-rank, p=0.443 and p=0.331, respectively) 
(Figure 4A, B) and OS (log-rank, p=0.848 and p=0.494, re-
spectively) (Figure 5A, B) according to CTC-positive status. 
Among patients with triple negative breast cancer, those with 
CTC-positive status had shorter MFS and OS (log-rank, p= 
0.051 and p=0.042, respectively) (Figure 4C, 5C). Patients 
with CTC-positive status in the HER2 subtype breast cancer 
group also had shorter MFS and OS (log-rank, p=0.004 and 
p=0.026, respectively) (Figure 4D, 5D). 
Based on Cox multivariate analysis, CTC status indepen-
dently predicted MFS (odds ratio [OR], 2.263; 95% confidence 
interval [CI], 1.006-5.092; p=0.048) (Table 2) but not OS (OR, 
2.363; 95% CI, 0.905-6.169; p=0.079) (Table 2). Among the 
molecular subtypes of operable breast cancer, only the triple 
negative subtype independently predicted MFS (OR, 2.910; 
95% CI, 1.151-7.359; p=0.024) (Table 2) and OS (OR, 5.077; 
95% CI, 1.650-15.623; p=0.005) (Table 2).
DISCUSSION
Using univariate analysis, we found no correlation between 
CK-20 mRNA-positive CTC and any previously established 
prognostic factor in operable breast cancer (Table 1). Recent 
reports present HER2 status as the only primary tumor char-
acteristic that reliably predicts the presence of CTCs [9,20]. 
Figure 3. Different prognostic significances of circulating tumor cells (CTC) according to lymph node status. (A) Metastasis-free survival (MFS) in pa-
tients with negative node status. (B) MFS in patients with positive node status. (C) Overall survival (OS) in patients with negative node status. (D) OS in 
patients with positive node status. *log-rank test.
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Figure 4. Metastasis-free survival (MFS) curves according to circulating tumor cells (CTC) status by breast cancer subtypes. (A) MFS in the luminal A 
subtype. (B) MFS in the luminal B subtype. (C) MFS in the triple negative breast cancer subtype. (D) MFS in the HER2 subtype. *log-rank test.
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Tao et al. [9] used a cell enrichment technique with laser scan-
ning cytometry to detect CTC in the peripheral blood. They 
considered a 2+ staining pattern for HER2/neu as a positive 
value and did not perform FISH to test the extent of gene am-
plification. Lang et al. [20] used the CellSearch
® system (Veri-
dex, Warren, USA) to detect CTC in 30-mL peripheral blood 
samples and used FISH to further investigate all cases with 2+ 
and 3+ staining patterns for HER2 to confirm the presence of 
gene amplification. However, these results should be interpret-
ed with caution due to the small number of cases with HER2 
positive status (n=13) in that study. We declined to determine 
HER2 gene amplification using FISH and excluded patients 
with HER2 2+ status from our study. This may explain the 
difference between our results and theirs. Also, the difference 
between our result and theirs is well explained by differences 
in experimental techniques. 
We also found that in patients with operable breast cancer, 
CK-20 mRNA-positive CTC predicted shorter MFS and OS, 
especially in the triple negative and HER2/neu subtypes. Igna-
tiadis et al. [17] reported for the first time that the presence of 
CK-19 mRNA-positive CTC predicted poor clinical outcomes 
(relapse and death) in patients with ER-negative but not ER-
positive early breast cancer. They explained this as a result that 
in the ER-negative group micrometastatic cells could be tar-
geted only by adjuvant chemotherapy, whereas in the ER-pos-
itive subgroup they could be controlled by both adjuvant che-
motherapy and hormone treatment. Similarly, we found that 
our patients with CK-20 mRNA-positive CTC had shorter 40   Seong Bae Hwang, et al.
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MFS and OS (log-rank p<0.05; data not shown) in the ER-
negative subgroup only. Ignatiadis et al. [17] also suggested 
that the presence of CK-19 mRNA-positive CTC was associ-
ated with shorter DFS and OS in the triple negative and HER2 
positive subgroups but not in the ER-positive/HER2 negative 
subgroup; this finding is in accordance with our findings [17]. 
There are some possible explanations for this result. Triple 
negative and HER2 breast cancer subtypes are well known for 
their poor prognosis and aggressive behavior [14-16]. Brain 
metastasis is more often observed from these breast cancer 
subtypes than other subtypes [21,22]. As such, these subtypes 
might give CTC in the peripheral blood more opportunities 
to develop local recurrence with eventual dissemination to 
distant sites due to failure of systemic therapy and the unknown 
intrinsic propensity to distant metastasis. Because HER2 breast 
cancer and triple negative breast cancer are subgroups of ER-
negative breast cancer, these patients did not receive hormone 
therapy after their surgical procedures. The discontinuity in 
systemic treatment after surgery may potentially provide time 
for the CTC to progress and migrate to distant sites. We did 
not treat our patients with HER2 positive breast cancer with 
trastuzumab after surgery because the positive trial results were 
not yet published at that time [23,24]. This may explain in part 
why patients in the HER2 breast cancer subgroup with CK-20 
mRNA-positive CTC had shorter MFS and OS. Further study 
is required to determine the prognostic significance of CTC in 
patients with HER2-positive breast cancer who are treated with 
trastuzumab.
Figure 5. Overall survival (OS) curves according to circulating tumor cells (CTC) status by breast cancer subtype. (A) OS in the luminal A subtype. (B) 
OS in the luminal B subtype. (C) OS in the triple negative breast cancer subtype. (D) OS in the HER2 subtype. *log-rank test.
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Our results suggest that the prognostic value of preopera-
tively detected CTC differs according to the molecular sub-
type of breast cancer. Interestingly, however, the biological 
characteristics of the CTC do not necessarily represent the 
molecular subtype of the primary tumor. In fact, a change in 
CTC character with respect to the primary tumor, especially 
HER2, may serve to monitor responses to targeted therapy 
and chemotherapy and help clinicians select patients who are 
most likely to benefit from secondary adjuvant treatment [18, 
25,26]. Pestrin et al. [26] reported that 29% (8/28) of HER2-
negative primary tumors had HER2-positive CTC and that 
42% (5/12) of HER2-positive primary tumors had HER2-
negative CTC. They then suggested that a subset of patients 
with HER2-negative primary tumors develops HER2-positive 
CTC during disease progression [26]. Unfortunately, we did 
not characterize the CTC in this study because the necessary 
RT-PCR reagents were not available.
Methods to detect CTC in the peripheral blood include RT-
PCR using mRNA, CellSearch
® (Veridex), CTC-chip, AdnaTest 
BreastCancer
TM (AdnaGen, Langenhagen, Germany), CAM 
method, MAINTRAC
® analysis (SYMPO, Bayreuth, Germa-
ny), Membrane microfilter assay, Fiberoptic array scanning 
technology (FAST), Epithelial immunospot assay (EPISPOT), 
and others [27,28]. Although RT-PCR has high sensitivity, its 
specificity is generally low and results in higher false positive 
rates, and molecular profiling assays of CTC could not be con-
ducted [18,22,24]. However, we used the CK-20 mRNA with 
RT-PCR method to detect CTC in the blood because our pre-
vious reports revealed that CK-20 was not expressed at all in 
normal healthy individuals or in patients with benign disease. 
This finding showed that CTC as detected by the CK-20 assay 
originate uniquely in malignant foci [12,19]. Many efforts have 
been made to enhance the sensitivity and specificity of RT-
PCR for detecting CTC in the peripheral blood [13,18]. Giri-
baldi et al. [13] developed a real-time RT-PCR method for de-
tecting CK-20 cells with two novel features: 1) a primer over-
lapping two adjacent exons to inhibit nonspecific amplifica-
tions and 2) a non-end-point first-round amplification to in-
crease sensitivity. In addition, the use of multi-marker real-time 
RT-PCR assays may potentially improve the method even in 
the case of a single down-regulated gene [18].
This study is limited most significantly by its retrospective 
design, which reduces the confidence of the study data. In ad-
dition, although we intended to assess the prognostic signifi-
cance of CTC in the peripheral blood according to breast can-
cer molecular subtype, we did not perform FISH to establish 
HER2 amplification in patients with HER2 2+ status. Instead, 
we excluded these patients from this study. Third, our study is 
limited by its small number of patients. Notwithstanding these 
limitations, to our knowledge, the current study is the first to 
evaluate the prognostic value of CK-20 mRNA-positive CTC 
according to molecular subtype based on long-term follow-up 
of patients with operable breast cancer. Our results may prompt 
other researchers to seek further correlations between CTC 
and breast cancer subtype. In the near future, CTC may become 
a useful parameter for predicting the prognosis of patients with 
operable breast cancer, particularly those with the triple nega-
tive and HER2 subtypes. 
CK-20 mRNA-positive CTC may present a clinically rele-
vant biological marker of tumor progression, especially in the 
triple negative and HER2 subtypes of operable breast cancer. 
Large scale prospective trials may be justified to assess the val-
ue of CTC determinations in planning treatment for and pre-
dicting outcome in these cancers.
Table 2. Multivariate analysis for risk factor of metastasis-free survival and overall survival in patients with operable breast cancer
Variables
Metastasis-free survival Overall survival
OR 95% CI p-value OR 95% CI p-value
CTC status, negative vs. positive 2.263 1.006-5.092 0.048 2.363 0.905-6.169 0.079
AJCC tumor stage, early vs. advanced
(Stage I/II vs. IIIA)
1.593 0.692-3.666 0.274 1.608 0.609-4.241 0.337
Lymphatic invasion, negative vs. positive 1.424 0.583-3.480 0.437 1.053 0.348-3.184 0.927
Vascular invasion, negative vs. positive 2.029 0.463-8.900 0.348 3.391 0.757-15.189 0.111
Molecular subtypes
Luminal A*
Luminal B 0.774 0.236-2.532 0.672 0.702 0.135-3.655 0.674
TNBC 2.910 1.151-7.359 0.024 5.077 1.650-15.623 0.005
HER2 2.491 0.785-7.906 0.121 3.800 0.939-15.373 0.061
OR=odd ratio; CI=confidential interval; CTC=circulating tumor cells; AJCC=American Joint Committee on Cancer; TNBC=triple negative breast cancer; HER2= 
human epidermal growth factor receptor 2.
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